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Abstract 
 
Introduction 
To report the observations of point-of-care (POC) HbA1c testing in people with non-diabetic 
hyperglycaemia (NDH; HbA1c 42-47mmol/mol (6.0-6.4%)), applied in community settings, within the 
English National Health Service Diabetes Prevention Programme (NHS DPP).  
 
Research Design and Methods 
A service evaluation assessing prospectively collected national service-level data from the NHS DPP, 
using data from the first referral received in June 2016 to October 2018.  Individuals were referred to 
the NHS DPP with a laboratory measured HbA1c in the NDH range and had a repeat HbA1c 
measured at first attendance of the programme using one of three POC devices; DCA Vantage, 
Afinion  or A1C Now+. Differences between the referral and POC HbA1c and the standard deviation 
(SD) of the POC HbA1c were calculated. The factors associated with the difference in HbA1c and the 
association between POC HbA1c result and subsequent attendance of the NHS DPP were also 
evaluated.     
 
Results 
Data from 73,703 participants demonstrated a significant mean difference between the referral and 
POC HbA1c of -2.48mmol/mol (-0.23%) (t=157,p<0.001) with significant differences in the mean 
difference between devices (F(2, 73,700)=738,p<0.001).  The SD of POC HbA1c was 4.46mmol/mol 
(0.41%) with  significant differences in SDs between devices (F(2, 73,700)=1,542, p<0.001).  
Participants who were older, from more deprived areas and from Asian, black and mixed ethnic 
groups were associated with smaller HbA1c differences. Normoglycaemic POC HbA1c vs. NDH POC 
HbA1c values were associated with lower subsequent attendance at behavioural interventions (58% 
vs. 67%,p<0.001).   
Conclusions 
POC HbA1c testing in community settings was associated with significantly lower HbA1c values when 
compared to laboratory-measured referrals. Acknowledging effects of regression to the mean, these 
differences were also associated with POC method, location, individual patient-factors and time 
between measurements. Compared to POC HbA1c values in the NDH range, normoglycaemic POC 
HbA1c values were associated with lower subsequent intervention attendance. 
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What is already known about this subject?  
Point-of-care (POC) HbA1c devices are increasingly used in community settings and may vary in 
performance.  
What are the new findings? 
POC HbA1c measurements within the NHS DPP were significantly lower when compared to referral 
HbA1c measurements. These differences were associated with the POC assay, it’s location of use, 
individual patient-factors (including deprivation status, age and ethnicity) and the time between 
measurements.  
How might this impact on clinical practice in the foreseeable future?  
Practitioners using POC HbA1c  devices to assess people with NDH should be aware of factors 
associated with differences in HbA1c values but crucially the impact of these values on interpretation 
and on subsequent attendance at behavioural interventions.  
 
• POC HbA1c measurements within the National Health Service Diabetes Prevention Programme 
were significantly lower when compared to referral venous laboratory HbA1c measurements. 
• Acknowledging the effects of regression to the mean, the differences observed were also  
associated with the POC device used, individual patient factors and time between measurements. 
• The decrease moved a proportion of people into the normoglycaemic range, who were then less 
likely to attend behavioural interventions. 
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Introduction 
In 2016, the Healthier You: National Health Service Diabetes Prevention Programme (NHS DPP) was 
developed to prevent or delay onset of type 2 diabetes in adults in England identified with non-diabetic 
hyperglycaemia (NDH) (glycated haemoglobin (HbA1c) 42-47mmol/mol (6.0-6.4%) or fasting plasma 
glucose (FPG) 5.5–6.9mmol/l).[1] The NHS DPP delivers behavioural interventions based on guidance 
from the National Institute for Health and Care Excellence (NICE) via Provider organisations who used 
serial point-of-care (POC) HbA1c testing to track responses to interventions.[2]   
Routine internal monitoring of the programme indicated a significant mean difference between 
laboratory measured HbA1c values obtained on referral to the programme  (undertaken by referring 
general practices)  and values obtained  on first attendance of the programme, where HbA1c was re-
measured using a POC device.  
Differences in an HbA1c level measured at two time points may reflect regression to the mean, a 
genuine biological change, or variation in the testing methodology used. The demographic, individual 
patient or assay-related factors that affect change in HbA1c outside of the diabetes range are not well-
studied. This knowledge is vital however, if serial measurements are used in people with NDH, which 
represents a narrow clinical range of interest, and where small changes in HbA1c have the potential to 
diagnose type 2 diabetes at one extreme or declassify NDH status at the other. 
Using data from the first 28 months of the NHS DPP, we aimed to 
1) Determine if there were significant differences between laboratory measured HbA1c and 
subsequent POC HbA1c measurements across all devices and testing pathways in the NHS 
DPP 
2) Identify modifiable and non-modifiable factors associated with observed differences between 
laboratory measured HbA1c and POC measured HbA1c in the NHS DPP 
3) Assess the association between POC re-measurements of HbA1c and subsequent attendance 
of the NHS DPP . 
The study does not attempt to assess the performance of POC devices in the measurement of HbA1c 
but rather to examine the implications of their use in a community setting as a follow up to a laboratory 
HbA1c measurement. 
Research Designs and Methods  
Study design 
A service evaluation in England assessing prospectively collected national service-level data from the 
NHS DPP using data from the first referral received in June 2016 to October 2018. 
Intervention 
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The NHS DPP delivers behavioural interventions encouraging weight loss in those overweight or obese, 
increased physical activity and healthier diets, through a minimum of 13 face-to-face group-based 
sessions, over at least 9 months, constituting at least 16 hours of contact-time.  Over this time period, 
interventions were delivered by one of four service Providers selected as part of a national competitive 
procurement process: Reed Momenta Ltd (London, UK), ICS Health and Wellbeing (Leeds, UK), Ingeus 
UK Ltd (London, UK), and Living Well Taking Control LLP (Birmingham, UK).  
Participants 
Individuals with a test result indicating NDH within the previous 12 months, aged 18 years or over, not 
pregnant and not previously diagnosed with Type 2 diabetes were identified from NHS Health 
Checks,[3] general practice records or routine clinical practice. The majority of referrals included HbA1c 
results from laboratory testing, rather than FPG, although testing methodology was not stipulated.  
Individuals referred to the programme were invited to attend an Initial Assessment (IA) during which 
further details of the programme were provided, and participants were assigned to a group for 
intervention delivery.  
Data collection 
Programme providers were contractually required to collect a minimum dataset;  age, sex, post-code, 
the referral HbA1c/FPG and optionally, weight, were recorded on referral; ethnicity, weight and height 
at IA.  Providers were contractually required to assess HbA1c at IA if the referral HbA1c or FPG was 
assessed more than 3 months previously.  This service evaluation involved assessment of anonymised 
data collected during routine service delivery; NHS England has published an information governance 
framework setting out the legal basis for data collection and data flows, ensuring that the service and 
its evaluation are delivered in compliance with data protection legislation.[4] 
Sex was recorded as male, female or indeterminate. Recorded ages were grouped (to align with both 
NHS health checks and retirement age) into <40, 40-64, 65-74 and 75+ years and self-reported ethnicity 
as white, Asian, black, mixed or other.  Deprivation scores were obtained using Lower Super Output 
Area (derived from participant postcode) linked to the deprivation quintile from the Index of Multiple 
Deprivation.  BMI was calculated for participants who had weight and height recorded at IA.  All variables 
also include an unknown category where either the participant declined to give the relevant information, 
or where a value was not recorded. 
POC Devices 
An expert working group was established to advise on internationally stipulated minimum performance 
criteria for HbA1c within the programme and provided more specific guidance around use of POC 
devices,[5] including calibration to the International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) reference measurement procedure (RMP); and that Medicines and Healthcare 
products Regulatory Authority (MHRA) guidance around the provision of a quality framework, including 
internal quality control and external quality assessment (EQA) to support POC delivery, be followed.[6] 
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EQA, a process by which individual analytical devices can be compared to a reference or other devices, 
captures device bias and, with serial assessment, changes in analytical performance over time for any 
single device. Deviation in EQA performance can be investigated and resolved. 
The four Providers used HbA1c POC devices: DCA Vantage (Siemens Healthcare Ltd, Guildford, UK), 
Afinion  (Abbott Diagnostics, Maidenhead, UK) or A1C Now+ (BHR Pharmaceutical Ltd, Nuneaton, UK).  
A ‘POC pathway’ was defined as the combination of the device used and the location where testing 
was performed - either a Lloyds pharmacy (subcontracting arrangements used by two Providers) or “in-
house” (a community venue where a Provider delivered the intervention). Pathways are listed in Table 
1. Providers used the same device and pathway for each participant.  Though not contractually required, 
in some individuals Providers undertook POC HbA1c within 3 months of the referral HbA1c.  
Table 1: Provider pathways and devices used by the NHS Diabetes Prevention Programme 
Provider Pathway Device 
Living Well Taking Control - Provider 1 Afinion 
ICS Health and Wellbeing - Provider 2 DCA Vantage 
Reed via Lloyds Pharmacy  - Provider 3 A1c Now+ 
Reed in-house pathway - Provider 3 A1c Now+ 
Ingeus via Lloyds Pharmacy - Provider 4 A1c Now+ 
Ingeus in-house pathway - Provider 4 DCA Vantage 
 
Outcomes 
The primary outcomes were the difference in HbA1c between laboratory measured HbA1c and 
subsequent POC measured HbA1c and standard deviation (SD) of  POC measured HbA1c.  The factors 
associated with the difference in HbA1c and the association between IA POC HbA1c and subsequent 
attendance were also evaluated. 
The HbA1c difference between referral and IA and the SD of IA POC HbA1c were calculated for 
participants with a valid HbA1c recorded at both referral and IA. For a subgroup of participants with 
available data, the relationship between recorded HbA1c difference and weight change was examined.  
In those who had had sufficient time to attend, the relationship between IA POC HbA1c results and 
subsequent attendance at the group-based behavioural intervention sessions was studied, by grouping 
individuals according to IA POC HbA1c values as normoglycaemic (<42 mmol/mol), NDH (42-
47.9mmol/mol) and Type 2 diabetes range (>48 mmol/mol). 
Statistical Analysis 
A paired t-test was used to test for differences between the mean referral and mean IA HbA1c and a 
one-way analysis of variance was used to determine differences in the mean HbA1c change at IA.  
Where the null hypothesis for Bartlett’s test for equality of variances was rejected, Kruskal-Wallis 
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equality of population rank test was also undertaken.  Levene’s test was used to test equality of SDs 
between pathways.    
Mixed effects linear regression models were used to identify factors associated with differences in 
HbA1c.  In Model One, pathway, referral HbA1c, time (days) between referral HbA1c and IA HbA1c, 
and participant characteristics (age, sex, ethnicity and deprivation) were considered as fixed effects and 
local referral area as a random effect with the contribution of the random effect quantified using the 
Intraclass Correlation Coefficient (ICC).  Local referral areas are only associated with a single provider 
and therefore incorporate the same facilities and facilitators used by that provider.  Variation between 
the four providers was directly accounted for by a fixed effect in the model. Model Two substituted 
pathway for device, with other variables remaining the same. Model three included weight change 
between referral and IA. A mixed-effects logistic regression model was used to identify factors 
associated with attendance of at least one intervention session following IA and was applied to the 
subgroup who had had at least 6 months to attend an intervention session.   Pathway, participant 
characteristics (including BMI at IA) and POC HbA1c grouping at IA were considered as fixed factors 
and local referral area as a random effect. Only participants from the given subgroup for whom all data 
fields were complete were included in the regression analyses. 
Sensitivity analyses were conducted on the regression models using multiple imputation, employing 
the Multivariate Chained Equations approach  to impute missing data and then comparing the results 
to the primary analyses.[7] We used the Fraction of Missing Information as a rule of thumb to estimate 
the number of imputations needed and imputed missing values for age, deprivation, sex, ethnicity and 
BMI.  All participants had recorded data for pathway, local referral area, referral HbA1c and IA HbA1c. 
Statistical significance was defined as p-value<0.05.  Where there were multiple comparisons, a post-
hoc Bonferroni correction was applied.   Confidence Intervals (Cis) were set at 95%.  All data were 
analysed using Stata version 15. 
Results 
HbA1c at referral 
Overall 73,703 participants had an HbA1c measurement at both referral and IA.  Characteristics of 
participants are provided in Table 2; 44% of participants were male, the mean (SD) age was 64 (12) 
years and 20% were of black, Asian, mixed or other (BAME) ethnicity, 65% white and 16% unknown.  
There was broadly equal representation from all deprivation quintiles.  The mean (SD) HbA1c at referral 
was 43.7(1.5) mmol/mol (6.1(0.14)%).  Though statistically significant differences, there were no 
clinically meaningful differences in the mean (SD) referral HbA1c by pathway, ranging from 43.6 (1.5) 
mmol/mol (6.1 (0.14) %) to 43.8 (1.5) mmol/mol (6.2 (0.14) %). Data were missing for; age (<0.01%), 
sex (0.6%), ethnicity (15.7%) and deprivation (0.4%).  There were no missing data for referral HbA1c, 
IA HbA1c and pathway and device.   
HbA1c at Initial Assessment 
8 
 
The mean (SD) number of days between HbA1c measurements was 203 (120) days.  The mean (SD) 
IA HbA1c was 41.2 (4.46) mmol/mol (5.9 (0.41) %), a significant difference of -2.48mmol/mol (-0.23%) 
from the mean referral HbA1c (t=157,p<0.001). Significant differences were observed for all pathways 
and for all devices (Table 2).  Mean differences were significantly different between pathways (F(5, 
73,697)=374,p<0.001) and between devices (F(2, 73,700)=738, p<0.001), with significant differences 
for 11 of the 15 pairwise combinations of pathways and all pairwise combinations of devices 
(Supplementary Tables S1 and S2).There were significant differences in the SD of the HbA1c at IA 
between pathways (F(5, 73,697)=598.9, p<0.001) and devices (F(2, 73,700)=1541.8, p<0.001) (Table 
2).  There were no significant differences in the SD between pathways using the same device.  There 
were significant differences between the DCA Vantage and A1c Now+ devices (F(1, 
62,133)=2186.6,p<0.001), Afinion and A1c Now+ devices F(1, 42,832)=1548.4,p<0.001) and Afinion 
and DCA Vantage devices F(1, 42,502)=68.0, p<0.001). 
Factors associated with the change in HbA1c from referral to IA 
Univariate analyses of outcomes are provided in Table 2.  HbA1c differences between referral and IA 
measurements became larger as the number of days between measurements increased from the <28 
days category up to the  84-111 days category, then reduced as the number of days increased further 
(Figure 1, panel A). The SD of the HbA1c at IA increased as the number of days between measurements 
increased (Figure 1, panel B). Regression analysis indicated that for each 1.0mmol/mol higher value of 
referral HbA1c, there was a corresponding 0.2mmol/mol greater difference between referral and IA 
POC HbA1c (Table 3).  POC pathway had a significant association with observed HbA1c difference; 
using the ICS Health and Wellbeing (DCA Vantage) pathway (which had the greatest number of 
participants) as a reference, no difference in the magnitude of reduction was observed for the Ingeus 
(DCA Vantage) pathway, however all other pathways were associated with a greater HbA1c difference.  
Measurements from participants who were older or from more deprived areas were associated with 
smaller HbA1c differences, but there was no effect of sex. Relative to white groups, Asian, black and 
mixed ethnic groups had a smaller HbA1c difference. Clustering by local referral area made a 
proportionally small contribution to the outcomes (ICC 3.7(2.6-5.4)%).   In Model Two, device was found 
to be significantly associated with HbA1c difference; Afinion and A1C Now+ devices were both 
associated with larger differences compared to the DCA Vantage device (supplementary Table S3). 
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Table 2: Mean HbA1c laboratory measurement at Referral, point-of-care (POC) re-measurement at Initial Assessment (IA), change in HbA1c between 
referral and IA and Standard deviation (SD) of IA HbA1c by device,  pathway and participant characteristics  
  
 N % 
Mean 
referral 
HbA1c 
mmol/mol 
SD of 
referral 
HbA1c 
mmol/mol 
Mean IA 
POC 
HbA1c 
mmol/mol 
Mean change in 
HbA1c (95% CI) 
mmol/mol 
P value 
(paired t-
test) 
P value 
(one-way 
ANOVA)** 
SD of IA POC 
HbA1c (95% CI) 
mmol/mol 
Overall 73,703  43.7 1.5 41.2 -2.48 (-2.51 to -2.45) <0.001 n/a 4.46 (4.44 to 4.48) 
Device A1c Now+ 31,230 42% 43.6 1.5 40.6 -3.04 (-3.10 to -2.99) <0.001 <0.001 5.28 (5.24 to 5.33) 
  Afinion 11,586 16% 43.7 1.5 40.8 -2.85 (-2.91 to -2.79) <0.001  3.35 (3.30 to 3.39) 
  DCA Vantage 30,887 42% 43.7 1.5 41.9 -1.78 (-1.82 to -1.74) <0.001   3.75 (3.72 to 3.78) 
Pathway 
ICS Health and 
Wellbeing (DCA 
Vantage) 
29,422 40% 43.7 1.5 42.0 -1.76 (-1.80 to -1.72) <0.001 <0.001 3.74 (3.71 to 3.77) 
  
Ingeus Inhouse 
(DCA Vantage) 
1,465 2% 43.6 1.5 41.4 -2.18 (-2.37 to -2.00) <0.001  3.89 (3.76 to 4.04) 
  
Ingeus Lloyds 
(A1c Now+) 
4,108 6% 43.6 1.5 39.4 -4.23 (-4.38 to -4.08) <0.001  5.06 (4.95 to 5.17) 
  
Living Well 
Taking Control 
(Afinion) 
11,586 16% 43.7 1.5 40.8 -2.85 (-2.91 to -2.79) <0.001  3.35 (3.30 to 3.39) 
  
Reed Inhouse 
(A1c Now+) 
26,767 26% 43.6 1.5 40.8 -2.86 (-2.93 to -2.80) <0.001  5.30 (5.25 to 5.34) 
  
Reed Lloyds 
(A1c Now+) 
355 0% 43.8 1.5 40.9 -2.86 (-3.34 to -2.39) <0.001  4.86 (4.53 to 5.25) 
Sex Male 32,561 44% 43.7 1.5 41.2 -2.51 (-2.56 to -2.47) <0.001 0.2259** 4.62 (4.59 to 4.66) 
  Female 40,684 55% 43.7 1.5 41.2 -2.46 (-2.50 to -2.42) <0.001  4.33 (4.30 to 4.36) 
  Indeterminate 49 0% 43.6 1.4 41.4 -2.25 (-3.81 to -0.69) 0.01  5.53 (4.61 to 6.91) 
  Unknown 409 1% 43.7 1.5 41.5 -2.27 (-2.61 to -1.93) <0.001   3.62 (3.38 to 3.88) 
Age <40 * * 43.6 1.5 41.2 -2.41 (-2.62 to -2.21) <0.001 <0.001 5.53 (5.38 to 5.68) 
  40-64 30,483 41% 43.7 1.5 41.4 -2.33 (-2.38 to -2.28) <0.001  4.74 (4.70 to 4.78) 
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 N % 
Mean 
referral 
HbA1c 
mmol/mol 
SD of 
referral 
HbA1c 
mmol/mol 
Mean IA 
POC 
HbA1c 
mmol/mol 
Mean change in 
HbA1c (95% CI) 
mmol/mol 
P value 
(paired t-
test) 
P value 
(one-way 
ANOVA)** 
SD of IA POC 
HbA1c (95% CI) 
mmol/mol 
  65-74 25,228 34% 43.7 1.5 41.1 -2.60 (-2.65 to -2.55) <0.001  4.21 (4.17 to 4.25) 
  75+ 15,388 21% 43.7 1.5 41.1 -2.60 (-2.66 to -2.54) <0.001  4.05 (4.01 to 4.10) 
  Unknown * * * * * * * * * 
Ethnicity Asian 7,998 11% 43.8 1,6 41.8 -2.06 (-2.15 to -1.97) <0.001 <0.001 4.21 (4.15 to 4.28) 
  Black 4,917 7% 43.8 1.5 42.3 -1.48 (-1.63 to -1.33) <0.001  5.36 (5.26 to 5.47) 
  Mixed 1,009 1% 43.6 1.5 42.0 -1.65 (-1.90 to -1.40) <0.001  4.12 (3.95 to 4.31) 
  Other 624 1% 43.7 1.5 40.8 -2.84 (-3.21 to -2.46) <0.001  4.96 (4.70 to 5.25) 
  White 47,610 65% 43.6 1.5 41.1 -2.55 (-2.59 to -2.52) <0.001  4.12 (4.09 to 4.14) 
  Unknown 11,545 16% 43.7 1.5 40.7 -2.97 (-3.06 to -2.88) <0.001   5.36 (5.29 to 5.43) 
Deprivation 
IMD 1 (most 
deprived) 
15,031 20% 43.7 1.5 41.6 -2.12 (-2.19 to -2.05) <0.001 <0.001 4.82 (4.77 to 4.88) 
  IMD 2 14,700 20% 43.7 1.5 41.4 -2.31 (-2.38 to -2.24) <0.001  4.59 (4.54 to 4.64) 
  IMD 3 15,098 20% 43.7 1.5 41.2 -2.47 (-2.53 to -2.40) <0.001  4.33 (4.28 to 4.38) 
  IMD 4 14,389 20% 43.7 1.5 40.9 -2.71 (-2.77 to -2.64) <0.001  4.23 (4.18 to 4.28) 
  
IMD 5 (least 
deprived) 
14,163 19% 43.6 1.5 40.8 -2.83 (-2.90 to -2.76) <0.001  4.25 (4.20 to 4.30) 
  Unknown 322 0% 43.6 1.5 40.7 -2.97 (-3.38 to -2.56) <0.001   3.86 (3.59 to 4.19) 
 
* Suppressed due to small numbers 
**The  Bartlett’s test for equality of variances was rejected in all cases. The K-wallis test gave the same result as the ANOVA in term of significance with the exception of Sex where it indicated a 
significant difference (p <0.0055). 
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Association of HbA1c change with weight 
A subset of 20,576 participants had available weight measurements at referral and IA. At referral, the 
mean (SD) weight was 81.7(18.3) kg and mean (SD) HbA1c, 43.6 (1.5) mmol/mol (6.1 (0.14) %).  The 
mean weight change between referral and IA was +1.4kg (t= 39.8,p<0.001)) with 56% of participants 
gaining weight, 17% remaining the same and 27% losing weight. The mean HbA1c difference between 
referral and IA for those with recorded weight measures was -3.13mmol/mol (-0.29%) (t=95,p<0.001). 
A reduction in the mean HbA1c was observed across all weight change categories (gaining 
weight/remaining the same/losing weight). Incorporating weight into the regression model (Model 
Three) showed that change in the referral weight had a small, but significant positive association with 
the change in HbA1c; for each 1kg increase in weight there was 0.06 mmol/mol smaller decrease in 
HbA1c  (supplementary Table S4). The ICC was 1.8 (0.9-3.7)%. 
Association between POC HbA1c result and attendance at subsequent intervention session 
Studying only those who had sufficient time to attend an intervention session (46,894), 48% of HbA1c 
measurements were in the normoglycaemic range, 46% in the NDH range and 6% in the type 2 diabetes 
range. Participants with an IA POC HbA1c in the normoglycaemic range had significantly lower 
subsequent attendance at an intervention session compared to those in the NDH range (58% vs. 67%; 
p<0.001).  Logistic regression analysis indicated that participants who were older, up to 74 years, 
female, from less deprived areas and with a higher BMI, were more likely to attend a subsequent  
intervention session. It also confirmed lower attendance for those with IA POC HbA1c in the 
normoglycaemic  range, even after adjusting for other factors (Table4 ). The ICC was 26.1(18.3-35.8)%.  
Sensitivity analyses conducted by re-running the regression models using imputed data showed no 
changes in direction and magnitude of the associations (supplementary Tables S5-8).  
 
Table 3: Difference between laboratory measured HbA1c at Referral and Point-of-Care re-
measurement at Initial Assessment by pathway (N=61,623), mixed effects linear regression 
    Coefficient 
95% lower 
CI 
95% upper 
CI 
Standard 
error 
P value 
  Referral HbA1c Reading -0.20 -0.22 -0.18 0.01 <0.001 
Pathway 
ICS Health and Wellbeing 
(DCA Vantage) 
          
  
Ingeus Inhouse ( DCA 
Vantage) 
-0.34 -0.93 0.24 0.30 0.25 
  Ingeus Lloyds (A1c Now+) -2.18 -2.77 -1.60 0.30 <0.001 
  
Living Well Taking Control 
(Afinion) 
-0.85 -1.37 -0.32 0.27 <0.001 
  Reed Inhouse (A1c Now+) -0.98 -1.58 -0.39 0.30 <0.001 
  Reed Lloyds (A1c Now+) -1.83 -2.57 -1.09 0.38 <0.001 
Sex Male           
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    Coefficient 
95% lower 
CI 
95% upper 
CI 
Standard 
error 
P value 
  Female 0.00 -0.06 0.07 0.03 0.993 
  Indeterminate 0.82 -0.37 2.01 0.60 0.18 
Age group <40           
  40-64 0.34 0.16 0.52 0.09 <0.001 
  65-74 0.38 0.19 0.56 0.10 <0.001 
  75+ 0.41 0.22 0.61 0.10 <0.001 
Ethnicity White           
  Asian 0.36 0.25 0.47 0.06 <0.001 
  Black 0.93 0.80 1.07 0.07 <0.001 
  Mixed 0.63 0.38 0.88 0.13 <0.001 
  Other 0.15 -0.17 0.47 0.16 0.35 
Deprivation IMD 1 (most deprived)           
  IMD 2 -0.11 -0.22 -0.01 0.05 0.03 
  IMD 3 -0.19 -0.29 -0.09 0.05 <0.001 
  IMD 4 -0.28 -0.39 -0.17 0.05 <0.001 
  IMD 5 (least deprived) -0.34 -0.45 -0.23 0.06 <0.001 
Number of 
days 
between 
referral 
and IA 
HbA1c 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
<28 days           
28-55 days -0.72 -1.06 -0.38 0.17 <0.001 
56-83 days -0.98 -1.31 -0.65 0.17 <0.001 
84-111 days -1.51 -1.83 -1.20 0.16 <0.001 
112-139 days -1.31 -1.63 -0.99 0.16 <0.001 
140-167 days -1.31 -1.63 -0.99 0.16 <0.001 
168-195 days -1.17 -1.50 -0.85 0.17 <0.001 
196-223 days -1.09 -1.41 -0.76 0.17 <0.001 
224-251 days -1.12 -1.45 -0.79 0.17 <0.001 
252-279 days -1.06 -1.39 -0.73 0.17 <0.001 
280-307 days -0.99 -1.33 -0.66 0.17 <0.001 
308-335 days -0.89 -1.23 -0.55 0.17 <0.001 
336-363 days -0.67 -1.01 -0.33 0.17 <0.001 
363-739 days -0.81 -1.13 -0.49 0.16 <0.001 
>730 days -0.84 -1.72 0.03 0.45 0.06 
  Constant 7.63 6.61 8.65 0.52 <0.001 
 
Random-effects Parameters Estimate Std. Err. 95% lower 95% upper 
Local referral area: Identity         
var(_cons) 0.61 0.12 0.42 0.89 
var(Residual) 15.68 0.09 15.51 15.86 
 
LR test vs. linear model: chibar2(01) = 1619.49  Prob>=chibar2=<0.001 
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Table 4: Attendance of at least one Intevention Session in the NHS Diabetes Prevention 
Programme after Initial Assessment (N=33,544), mixed effects logistic regression  
    
Odds 
ratio 
95% 
lower CI 
95% 
upper CI 
P value 
Pathway** 
ICS Health and Wellbeing (DCA 
Vantage)  
      
  Living Well Taking Control (Afinion) 2.17 0.99 4.75 0.05 
  Reed Inhouse (A1c Now+) 1.67 0.72 3.86 0.23 
  Reed Lloyds (A1c Now+) 1.62 0.65 4.05 0.3 
Sex Male       
  Female 1.07 1.02 1.12 0.01 
  Indeterminate 0.76 0.34 1.67 0.49 
Age <40         
  40-64 1.64 1.43 1.88 <0.001 
  65-74 2.37 2.06 2.73 <0.001 
  75+ 1.90 1.64 2.20 <0.001 
Ethnicity White       
  Asian 1.09 1.00 1.18 0.05 
  black 1.30 1.18 1.44 <0.001 
  mixed 1.17 0.97 1.41 0.1 
  other 1.28 0.95 1.71 0.1 
Deprivation IMD 1 (most deprived)         
  IMD 2 1.17 1.09 1.26 <0.001 
  IMD 3 1.29 1.20 1.40 <0.001 
  IMD 4 1.33 1.23 1.44 <0.001 
  IMD 5 (least deprived) 1.46 1.34 1.59 <0.001 
BMI at Initial 
Assessment 
Underweight/healthy       
  Overweight 1.16 1.08 1.24 <0.001 
  Obese 1.27 1.18 1.36 <0.001 
HbA1c 
measurement 
at Initial 
Assessment 
NDH (>  42 to < 48  mmol/mol)         
Normoglycaemic  (<42mmol/mol) 0.71 0.67 0.75 <0.001 
Diabetes  >(47mmol/mol)* 0.32 0.28 0.35 <0.001 
 
Random-effects Parameters Estimate Std. Err. [95% Conf. Interval] 
          
Local referral area: Identity         
var(_cons) 1.16 0.27 0.74 1.84 
 
LR test vs logisitic model: chibar = 1851.98 Prob>=chibar2= <0.001 
*Participants with a HbA1c > 51 mmol/mol are taken off the Programme and put on to Type 2 diabetes 
treatment pathways **For Ingeus, the Intial Assessment is spread across the first intervention session 
and not comparable to other providers, therfore was not included in the regression analysis   
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Conclusion 
Summary of key findings 
Data from 73,703 participants in the NHS DPP show significant reductions between referral laboratory 
measured HbA1c and HbA1c re-measured using a POC device on first attendance of the programme. 
Acknowledging the effects of regression to the mean, the magnitude of the reduction in HbA1c observed 
was associated with the POC device used, the POC testing pathway, individual participant factors 
including age, ethnicity and social deprivation, and time between measurements. Furthermore, 
reductions in HbA1c were greater than concurrent weight change would suggest is attributable to 
behaviour change, although it is possible that other behavioural modification, independent of weight 
change, and not captured in this study, were also associated with the mean HbA1c difference.  POC 
HbA1c in the normoglycemic range were associated  with lower subsequent intervention attendance.  
However, it is important to note that this study does not attempt to assess the accuracy of POC testing, 
but rather examines the implications of using POC in the NHS DPP.   
Use of POC HbA1c devices  
There is increasing interest in the use of POC diagnostics internationally, where the provision of results 
in real-time might positively impact patient care.[8]  Despite reasonable POC HbA1c testing 
performance in laboratory method evaluations, performance has been variable in some research 
studies,[9-11] although newer generation analysers have shown improved analytical performance. [12-
13]  While the use of POC HbA1c in community settings has generated interest,[14-18] performance of 
POC HbA1c away from highly regulated, specialist supported laboratories within the narrow NDH range, 
remains unclear. 
The NHS DPP does not generate contemporaneously measured POC and laboratory-measured HbA1c 
and cannot robustly validate POC device performance against a reference. However, significant 
differences in the mean HbA1c between referral and IA were demonstrated for all pathways and 
devices. POC pathway and device had significant associations with the observed HbA1c difference, 
independent of other variables, including the time between measurements. The association of higher 
referral HbA1c values with larger differences suggests regression to the mean.  However, the mean 
HbA1c differences were significantly larger for all devices and pathways than the mean HbA1c 
differences between two laboratory HbA1c measurements as part of a previously published regional 
study, the Norfolk Diabetes Prevention Study.[19, 20]  While regression to the mean is likely 
contributory, there is no obvious reason why the contribution should be so much greater for NHS DPP 
compared to the previous regional study, although the regional population was smaller, less ethnically 
diverse with less variation by age and over a shorter time period. One potential explanation for the 
observed differences in our study is the introduction of a significant negative bias (attributable to both 
pathway and device) when POC HbA1c testing was applied in the community setting.   
The significant differences in the SDs of IA POC HbA1c between pathways may reflect differences in 
the level of training of the user, location and transportation of devices, or other factors such as device 
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maintenance and calibration, although the POC HbA1c device used was a significant independent 
factor with significant differences between all three devices, suggesting the underlying assay 
methodology was an important contributor. 
Use of POC HbA1c assays in the NDH range 
The IFCC taskforce (TF) published performance criteria for HbA1c methods using total allowable error, 
a concept applied to the measurement of any analyte that encompasses both assay bias and 
imprecision.[21]  Total allowable error that falls within the biological variability of an analyte or below 
the threshold for a clinically meaningful change is considered acceptable. For HbA1c, a total allowable 
error of 5mmol/mol is an internationally derived performance standard for HbA1c assays.[21,22] 
Laboratory environments are highly controlled with specialists available to identify errors and 
troubleshoot them quickly. In contrast, POC application in community settings may struggle with 
recognition of quality issues without adequate support.[18,21,22,23] Indeed, in one study, many non-
laboratory practitioners did not appreciate the impact of biological variability and analytical imprecision 
on small changes in HbA1c.[24]  However, while this allowable error is acceptable when applied to the 
values of HbA1c commonly encountered in diabetes care, it nearly completely traverses the NDH range, 
challenging meaningful interpretation despite appropriate quality frameworks.   
The EurA1c study assessed both laboratory and POC devices in different countries and settings, using 
the 5mmol/mol total allowable error criteria set by the IFCC TF.[25]  Data from the most recent round 
of this study showed a mean bias of +0.5mmol/mol and coefficient of variation (CV) of 4.1% in the UK. 
The Afinion device reported a bias of -1.7mmol/mol and CV of 3.3% and the DCA Vantage device a 
bias of -0.6mmol/mol and CV of 3.7%. The A1CNow device was not studied. These data reflect 
observations in the NHS DPP and suggest that bias of devices within the NHS DPP lie within the 
allowable error. 
Clinical implications of using POC HbA1c devices 
The use of HbA1c to track responses to interventions in those with NDH has not previously been 
evaluated in terms of reliability of results or effects on behaviour. It has been suggested that the 
immediacy of POC HbA1c results may have beneficial effects on motivation and behaviour.[26, 27]  
However, in this context, POC HbA1c testing in the NHS DPP moved a large proportion of people into 
the normoglycaemic range, which in turn was associated with reduced subsequent attendance, 
although regression to the mean may have accounted for some of this effect, irrespective of the 
methodology used for re-testing HbA1c. However, it is possible that other behavioural changes not 
captured in this study, may have influenced  participants decisions not to continue to attend the 
programme.[28] 
HbA1c measurements within the NHS DPP were only used to assess response to the intervention, and 
not for diagnosis. A POC HbA1c value in the diabetes range did lead to a repeat laboratory-measured 
HbA1c value, but POC HbA1c values in the normoglycaemic range were not repeated.  The risk of a 
delayed diagnosis of Type 2 diabetes resulting  from lower POC HbA1c values within the NHS DPP 
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should be mitigated by the routine application of NICE guideline PH38 [2], which recommends annual 
reassessment of glycaemic status for people with NDH. Annual rechecks of HbA1c in those with NDH 
in England will also be incentivised in future via general practice pay-for-performance.[29] 
The same POC HbA1c device and pathway was used for each individual to track response to the 
intervention, so at cohort level mean changes in HbA1c pre-/post-intervention provided a useful marker 
of overall programme effectiveness, irrespective of any potential negative bias and higher variability.[30]  
EQA is a reliable mechanism for identifying assay drift, and for identifying poor performance beyond 
total allowable error, although this relies on the ability to identify and resolve quality issues, which maybe 
challenging for non-specialists.[24]  Some national schemes where POC HbA1c has been implemented 
in standardised community locations have had some success, though performance is variable despite 
intensive education and not all devices can undergo EQA.[23,31]  
Other factors associated with HbA1c change 
Other significant associations in the change in HbA1c include age (with those under 40 years with the 
greatest decrease), ethnicity (Asian, black and mixed participants have a significantly smaller decrease 
compared to white participants), and socioeconomic status (with the least deprived having the greatest 
decrease). The change in HbA1c varied by the number of days between tests, with the HbA1c difference 
between referral and IA becoming larger from the <28 days category up to the 84-111 days category 
and then some decrease.  This could be consistent with people modifying their behaviour initially after 
diagnosis of non-diabetic hyperglycaemia (assuming at referral) and then lapsing. It is possible that the 
association between measurement change and some of the above-mentioned parameters  relates to 
differences in the extent of behaviour change following referral/diagnosis of non-diabetic 
hyperglycaemia and prior to attendance at IA.  However, using weight change between referral and IA 
as a surrogate for behaviour change, which shows more weight gain than weight loss, suggests against 
this. 
Limitations 
A limitation to the current analysis is that it is not possible to fully determine the extent of regression to 
the mean. The HbA1c reductions seen in these analyses were certainly much larger than those seen 
in a study applied to a very similar but smaller homogeneous population, where repeat values were also 
assessed after an interval,[19, 20] suggesting an impact of additional contributors in the current 
analyses.  
We assumed all referral HbA1c values were laboratory-measured, but a small proportion, although not 
routine practice in the UK, may have been POC-measured.  Differences in mean HbA1c reduction may 
also reflect variability in the referral HbA1c values from different laboratory methods, which were not 
harmonised across the programme but are all assumed to be IFCC-calibrated.  
There was a large variation in time between referral and IA. However, associations between HbA1c 
change and pathway and device were independent of time elapsed in the regression analyses.  We 
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were not able to formally assess bias of POC methods but used regression models to demonstrate that 
devices and pathways had associations with observed HbA1c differences.   
Device selection was left to the Providers who were supplied with guidance around expected minimum 
performance criteria.  
Conclusion 
In summary, we show that a variety of modifiable and non-modifiable factors are associated with 
differences between laboratory measured HbA1c in the NDH range and subsequent POC 
measurements in the NHS DPP,  including POC device but also, how it is used and implemented (POC 
pathway).  Critically, we show that  the difference in measured HbA1c may indicate values in the 
normoglycaemic range at IA and that this is associated with a reduction in subsequent attendance at 
diabetes prevention intervention sessions. We propose that particular attention be paid to the modifiable 
factors identified in this analysis, such as the POC device selected and pathway of implementation, as 
the observed changes in some cases have the potential to alter subsequent participant engagement 
with the programme.  
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Figure 1 
A. Mean HbA1c change between laboratory measured HbA1c at referral and Point-of-Care re-
measurement at Initial Assessment by the number of days between measurements and device  
B. Standard deviation of Initial Assessment Point-of-care re-measurement HbA1c by the number of 
days between HbA1c measurements and device 
 
